HealthQuill Visual adverse events
The USFDA has put on hold Blueprint Medicines Corporation's clinical trial of BLU-222 due to visual adverse events seen in some patients, according to a company statement.
Drugs Pharma

FDA puts on hold Blueprint Medicines’ clinical trial for solid cancers

The USFDA has put on hold Blueprint Medicines Corporation's clinical trial of BLU-222 due to visual adverse events seen in some patients, according.

Read More